Vioxx, FDA Health Advisory - Sept 30, 2004

On September 30, 2004, and FDA Health Advisory was issued announcing that Merck was announcing a voluntary withdrawal of Vioxx from the market due to safety concerns.  Vioxx was a commonly prescribed drug in the non-steroidal anti-inflammatory drug (NSAID) family.  It was approved by the FDA in 1999 for the management of pain and inflammation and was widely prescribed to arthritis sufferers.

A long term study of Vioxx on patients suffering from recurrent colon polyps was stopped early in September 2004 for safety reasons.  Subjects of the study using Vioxx showed an increased risk of heart attack and stroke compared to subjects taking a placebo.  Merck voluntarily pulled Vioxx from the market on September 30th.

Vioxx FDA Health Advisory News
GN News

• FDA To Consider Fate Of Diabetes Drug Avandia USA Today
FDA to consider fate of diabetes drug AvandiaUSA TodayThe Concept Capital report speculated that the FDA advisory panel might end up evenly split between allowing Avandia to stay on the market, with additional As FDA Meeting on Avandia Looms, IOM Delivers ReportWall Street Journal blogOur view on Avandia: Diabetes medication dispute highlights flaws in drug USA TodayFDA expected to weigh in on Avandia riskPhiladelphia InquirerThe Associated Pressall 985 news articles raquo
• NicOx Shares Tumble After FDA Turns Down Naproxcinod BusinessWeek
NicOx Shares Tumble After FDA Turns Down NaproxcinodBusinessWeekThe decline was the biggest since a 45 percent drop on May 13, when a US advisory panel recommended rejecting naproxcinod. The Food and Drug Administration NicOx Says FDA Didn39t Approve Use of Experimental Painkiller NaproxcinodBloombergall 13 news articles raquo
• Avandia On Trial PharmExec.com Blog
PharmExec.com blogAvandia on TrialPharmExec.com blogThe mid July FDA advisory committee meeting to decide the fate of GlaxoSmithKline39s Avandia rosiglitazone and more raquo
• Rosiglitazone Hearing Reveals NotSoRosy Rifts At FDA MedPage Today
Rosiglitazone Hearing Reveals Not So Rosy Rifts at FDAMedPage TodayThis week39s FDA advisory committee meeting on rosiglitazone Avandia drew back the curtain on the agency39s internal politics but left its final decision
• FDA Advisory Panel Recommends Keeping Avandia On The Market With Additional ...
Examiner.comFDA advisory panel recommends keeping Avandia on the market with additional Examiner.comAfter two days of hearings the 33 members of the FDA39s advisory panel voted to allow Avandia to stay on the market. Twelve of the 33 members had voted to